Ponatinib Tablets Ponaxen 15mg is a targeted tyrosine kinase inhibitor formulated specifically for the treatment of leukemias such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). By selectively inhibiting the BCR-ABL kinase, Ponaxen effectively obstructs the pathways that enable malignant cancer cell proliferation and survival, thereby controlling disease progression. Each tablet contains 15mg of Ponatinib, manufactured under rigorous pharmaceutical quality controls to guarantee consistency, stability, and patient safety. This medication is intended for use under strict medical supervision, wherein dosage regimens are customized to patient-specific conditions and treatment responses. Ponatinib Tablets Ponaxen 15mg offers healthcare providers a reliable and potent therapy option for patients unresponsive or intolerant to prior tyrosine kinase inhibitors, contributing substantially to leukemia management strategies.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Ponatinib 15mg per tablet |
| Therapeutic Class | Tyrosine Kinase Inhibitor |
| Indications | Treatment of Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) |
| Mechanism of Action | Blocks BCR-ABL kinase activity to inhibit cancer cell growth |
| Dosage Form | Oral tablets |
| Administration | Oral, as prescribed by healthcare professionals |
| Manufacturing Standards | Produced under stringent quality controls to ensure purity and efficacy |
| Packaging | Bottled tablets, quantity per bottle as per order specifications |
| Patient Monitoring | Requires regular monitoring for side effects and treatment response |
| Prescription Status | Prescription only medication |
| Attributes | Description |
|---|---|
| Tablet Strength | 15mg Ponatinib |
| Tablet Type | Film-coated oral tablet |
| Pharmacological Category | Antineoplastic Agent |
| CAS Number | 943319-70-8 |
| Shelf Life | Typically 24 months from manufacturing date |
| Storage Conditions | Store at 20°C to 25°C, protect from moisture and light |
| Manufacturer | Ponaxen Pharmaceuticals |
| Regulatory Approval | Approved for use under applicable regional medical safety authorities |
| Packaging Details | Bottles containing a specific number of 15mg tablets per order |
| Prescription Requirement | Prescription mandatory |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Ponatinib Tablets Ponaxen 15mg are specifically indicated for treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ponatinib selectively inhibits the BCR-ABL tyrosine kinase enzyme, blocking signaling pathways essential for the growth and survival of malignant leukemia cells.
Ponaxen is provided as 15mg film-coated oral tablets, with dosages prescribed by healthcare professionals based on patient condition and treatment response.
Yes, tablets should be stored between 20°C and 25°C, protected from moisture and light to maintain potency and stability.
No, Ponatinib Tablets Ponaxen 15mg is a prescription-only medication and requires authorization by a qualified healthcare provider.
Ponaxen is manufactured under stringent pharmaceutical quality standards, ensuring purity, safety, and consistent efficacy for effective leukemia treatment.
Inclusive of all taxes
You Save: 0
Bengaluru , India
Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler
GST- 29AQTPJ8785C1Z2
